Question · asked by 1 review

Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide: Non‐serious adverse events ‐ total number of participants

It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (very low certainty).

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide
Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (very low certainty).
Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis (2023) · Cochrane Headline outcomes only
RR 0.57 [0.15, 2.13]6 studies · 396 participantsVery low

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis
2023 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.